Modeling the metabolism of idarubicin to idarubicinol in rat heart: Effect of rutin and phenobarbital

Drug Metabolism and Disposition

Volumn 31, Issue 4, 2003, Pages 462-468

  Kang, Wonku ^a   Weiss, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; IDARUBICIN; IDARUBICINOL; PHENOBARBITAL; RUTOSIDE; VERAPAMIL;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG TRANSPORT; HEART MUSCLE METABOLISM; HEART PERFORMANCE; ISOLATED HEART; KINETICS; MALE; MICHAELIS CONSTANT; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; TRANSPORT KINETICS;

AMIODARONE; ANIMALS; ANTINEOPLASTIC AGENTS; DAUNORUBICIN; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; HEART; IDARUBICIN; KINETICS; MALE; PHENOBARBITAL; RATS; RATS, SPRAGUE-DAWLEY; RUTIN; TIME FACTORS; VASODILATOR AGENTS; VERAPAMIL;

ANIMALIA;

EID: 0037377917     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.4.462     Document Type: Article

References (32)

1. Behnia K and Boroujerdi M (1999) Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. J Pharm Pharmacol 51:1275-1282.
2. Cusack BJ, Mushlin PS, Voulelis LD, Li X, Boucek RJ Jr, and Olson RD (1993) Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol 118:177-185.
3. D'Argenio DZ and Schumitzky A (1997) ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles.
4. Forrest GL and Gonzalez B (2000) Carbonyl reductase. Chem Biol Interact 129:21-40.
5. Forrest GL, Gonzalez B, Tseng W, Li X, and Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158-5164.
6. Garner AP, Paine MJ, Rodriguez-Crespo I, Chinje EC, Ortiz De Montellano P, Stratford IJ, Tew DG, and Wolf CR (1999) Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res 59:1929-1934.
7. Gerkens JF (1987) Barbiturate inhibition of endothelium-dependent dilatation of blood- and Krebs-perfused rat tail arteries. Eur J Pharmacol 34:293-301.
8. Huet S, Bouvier A, Gruet MA, and Jolivet E (1996) Statistical Tools for Nonlinear Regression. pp 69-70, Springer, New York.
9. Kang W and Weiss M (2001) Influence of P-glycoprotein modulators on cardiac uptake, metabolism and effects of idarubicin. Pharm Res (NY) 18:1535-1541.
10. Kang W and Weiss M (2003) Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart. Effect of doxorubicin and hypothermia. Pharm Res (NY) 20:58-63.
11. Keefe DL (2001) Anthracycline-induced cardiomyopathy. Semin Oncol 4:2-7.
12. Landaw EM and DiStefano JJ III (1984) Multiexponential, multicompartmental and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol 246:R665-R677.
13. Licata S, Saponiero A, Mordente A, and Minotti G (2000) Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13:414-420.
14. Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R, and Chua BH (2002) Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 283:H254-H263.
15. Loveless H, Arena E, Felsted RL, and Bachur NR (1978) Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 38:593-598.
16. Ludden TM, Beal SL, and Sheiner LB (1994) Comparison of the Akaike information criteria, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 22:431-445.
17. Matis JH, Wehrly TE, and Gerald KB (1985) Use of residence time moments in compartmental analysis. Am J Physiol 249:E409-E415.
18. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, and Possati G (1995) Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Investig 95:1595-1605.
19. Minotti G, Parlani M, Salvatorelli E, Menna P, Cipollone A, Animati F, Maggi CA, and Manzini S (2001) Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. Br J Pharmacol 134:1271-1278.
20. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/ iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541-552.
21. Olson RD and Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076-3086.
22. Platel D, Pouna P, Bonoron-Adele S, and Robert J (1999) Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anti-Cancer Drugs 10:671-676.
23. Schroder JK, Kasimir-Bauer S, Seeber S, and Scheulen ME (2000) In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia. J Cancer Res Clin Oncol 126:111-116.
24. Schussler M, Holzl J, and Fricke U (1995) Myocardial effects of flavonoids from Crataegus species. Arzneim-Forsch 45:842-845.
25. Smeets M, Raymakers R, Muus P, Vierwinden G, Linssen P, Masereeuw R, and de Witte T (2001) Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance. Leukemia (Baltimore) 15:80-88.
26. Studenberg SD and Brouwer KL (1992) Impaired biliary excretion of acetaminophen glucuronide in the isolated perfused rat liver after acute phenobarbital treatment and in vivo pheno. barbital pretreatment. J Pharmacol Exp Ther 261:1022-1027.
27. Terasako K, Nakamura K, Toda H, Kakuyama M, Hatano Y, and Mori K (1994) Barbiturates inhibit endothelium-dependent and independent relaxations mediated by cyclic GMP. Anesth Analg 78:823-830.
28. Toffoli G, Sorio R, Aita P, Cnvellari D, Corona G, Bearz A, Robieux I, Colussi AM, Stocco F, and Boiocchi M (2000) Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin Cancer Res 6:2279-2287.
29. Weiss M and Kang W (2002) P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling. J Pharmacol Exp Ther 300:688-694.
30. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19:670-686.
31. Wirth H and Wermuth B (1992) Immunohistochemical localization of carbonyl reductase in human tissues. J Histochem Cytochem 40:1857-1863.
32. Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, and Brouwer KLR (2002) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30:962-969.